A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data
- 9 August 2015
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 41 (6) , 689-703
Abstract
Amiodarone (AMD) is one of the most effective drugs for rhythm control of atrial fibrillation. The use of AMD is also associated with adverse effects in multiple tissues. Both the parent compound and its major metabolite desethylamiodarone (DEA) contribute to the drug’s therapeutic and toxic action. The present study aimed to build a whole-body physiologically based pharmacokinetic (PBPK) model for AMD and DEA in rats. Pharmacokinetic data from multiple studies were collected. Some of the data were pooled together to develop the PBPK model; others were used to evaluate the model. Development of the model also involved in vitro to in vivo extrapolation based on in vitro metabolism data. The final model consisted of 11 tissue compartments, including therapeutic target organs and those to which AMD and DEA may be harmful. Model simulations were in good agreement with the observed time courses of the drug–metabolite pair in tissues, under various dosing scenarios. The key pharmacokinetic properties of AMD, such as extensive tissue distribution, substantial storage in the fat tissue, and long half-lives in many tissues, were closely reflected. The developed PBPK model can be regarded as the first step towards a PBPK–pharmacodynamic model that can used to mechanistically evaluate and explain the high adverse event rate and potentially to determine which factors are the primary drives for experiencing an adverse event.Keywords
This publication has 71 references indexed in Scilit:
- Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in ChildrenCPT: Pharmacometrics & Systems Pharmacology, 2013
- Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro DataPLOS ONE, 2013
- Population Pharmacokinetic Investigation for Optimization of Amiodarone Therapy in Japanese PatientsTherapeutic Drug Monitoring, 2011
- Identification of Amiodarone Metabolites in Human Bile by Ultraperformance Liquid Chromatography/Quadrupole Time-of-Flight Mass SpectrometryDrug Metabolism and Disposition, 2011
- Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published DataThe AAPS Journal, 2011
- Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug DevelopmentBioMed Research International, 2011
- Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathologyBritish Journal of Pharmacology, 2009
- Amiodarone-induced skin pigmentation: Q-switched laser therapy, an effective treatment optionHeart, 2007
- AmiodaroneDrugs, 1992
- Clinical Pharmacokinetics of AmiodaroneClinical Pharmacokinetics, 1984